Chatham House: Independent thinking on international affairs

Antimicrobial Resistance

Incentivizing Change towards a Global Solution
3-4 October 2013


Session One:  Overview
09:30 - 10.50

  • What is the scale of antimicrobial resistance?

  • What are the main drivers and impacts? Why is there renewed urgency in tackling it?

  • How are countries, regions, the international community and the private sector addressing the problem?

  • What are the obstacles to achieving solutions?

Professor David Heymann, Director, Centre on Global Health Security, Chatham House

Keynote Address
Professor Dame Sally Davies, Chief Medical Officer, UK (on the record)

Dr Ramanan Laxminarayan, Vice President, Public Health Foundation of India

Dr David Payne, Vice President, Anti-Bacterial Discovery Performance Unit, GlaxoSmithKline

Questions and discussion

10:50 - 11:20    Refreshments

Session Two: Maintaining Antibiotic Effectiveness and Controlling Resistant Infections
11:20 - 12:40

  • What can be done to maintain antibiotic effectiveness?

  • What particular issues do developing countries face?

  • What are the successful strategies for controlling the spread of resistant infections? How applicable are these in developing countries?

  • What are the barriers to behaviour change?

Professor Didier Pittet CBE, Director, Infection Control Programme and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine; Lead Advisor, WHO First Global Patient Safety Challenge: Clean Care is Safer Care

Dr Carmem Pessoa-Silva, Team Lead, World Health Organization

Professor Alison Holmes, Professor of Infectious Disease, Imperial College, London

Martha Gyansa-Lutterodt, Chief Pharmacist and Director of Pharmaceutical Services, Ministry of Health, Ghana

Dr Abdul Ghafur, Coordinator ‘Chennai Declaration’ of Medical Societies, India; Consultant, Infectious Diseases and Clinical Microbiology, Apollo Hospitals, India
Questions and discussion

12:40 - 14:00    Lunch

Session Three: Stimulating Drug development: Pipelines and Incentives
14:00 – 15:30

  • What is the nature of the shortfall in the current pipeline of new drugs?

  • How can market models for making new antibiotics be improved?

  • What new push and pull mechanisms have been tried?

  • What new approaches should be tried?

Andrew Jack, Pharmaceutical Correspondent, Financial Times

Dr Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, Worldwide Chairman, Pharmaceuticals

Dr Line Matthiessen, Head of Infectious Diseases and Public Health Unit, DG Research and Innovation, European Commission

Professor Kevin Outterson, Associate Professor,  Boston University

Dr Marco Cavaleri, Head of Anti-infectives and Vaccines, Scientific and Regulatory Management Department, European Medicines Agency

Dr Patrick Vink, Senior Vice President and General Manager of International Business,
Cubist Pharmaceuticals

Questions and discussion

15:30 - 16:00 Refreshments

Session Four: New Approaches to Diagnosis and Discovery
16:00 - 17:20

  • What progress is there on the development of new therapeutics with novel modes of action: from phages to stimulating innate immunity?

  • How can new diagnostics aid clinical trials?

  • What can new approaches such as whole genome sequencing and genomics deliver?

  • To what extent do vaccines provide the answer in the prevention of infections caused by antimicrobial resistant bacteria?

Professor Laura Piddock, Professor of Microbiology and Deputy Director, Institute of Microbiology and Infection, University of Birmingham; BSAC Chair in Public Engagement and Director, Antibiotic Action

Dr Rosanna Peeling, Professor and Chair of Diagnostics Research, London School of Hygiene and Tropical Medicine

Dr John Rex, Vice President and Head of Infection, Global Medicines Development, AstraZeneca

Dr Rino Rappuoli, Global Head of Vaccines Research, Novartis Vaccines & Diagnostics

Sir David Hopwood FRS, Emeritus Fellow,  John Innes Centre

Questions and discussion

17:20  End of day one and drinks reception hosted by Chatham House

Friday 4 October 2013

Session Five: Use in Food and Agriculture: Fostering Cooperation to Address The Threat to Human and Animal Health
09:30 - 11:20

  • To what extent is the use of antibiotics in agriculture, particularly in meat and fish production, an important factor in the development of resistance in humans?

  • What are the mechanisms for the transfer of resistance to humans?

  • What has already been done to reduce the use of antibiotics in animals? How successful are global initiatives such as ‘One Health’ in encouraging medical and veterinary doctors to address the problem as a shared responsibility?

  • What new approaches should be tried?  Do vaccines provide part of the solution?

Nigel Gibbens, Chief Veterinary Officer, Department for Environment, Food and Rural Affairs, UK

Keynote Address
09:30 Dr Bernard Vallat, Director General, World Organisation for Animal Health (on the record)

Dr Jørgen Schlundt, Director, National Food Institute, Technical University of Denmark

Professor Preeni Abeynayake, Department of Veterinary Public Health & Pharmacology, University of Peradeniya, Sri Lanka

Dr David Wallinga, Founder and Director, Healthy Food Action and Member, Keep Antibiotics Working

Dr Stephen Page, Advanced Veterinary Therapeutics and Honorary Associate, Faculty of Veterinary Science, University of Sydney

Dr Liz Wagstrom, Chief Veterinarian, National Pork Producers Council, USA

Questions and discussion

11:20 - 11:50 Refreshments


Session Six: Fostering Global Commitment to Combat the Problem
11:50 - 13:30

  • What can be learned from countries making the most progress? And how is this relevant to other countries?

  • How can governments, the private sector and other stakeholders work together to address this problem?

  • What can the WHO, the international community and countries do to strengthen national commitments to finding a solution?

  • Generating the political and public support for enhanced global action?

Professor Dame Sally Davies, Chief Medical Officer, UK

Keynote Address
Dr Margaret Hamburg, Commissioner, US Food and Drug Administration (on the record)

Moderated Panel Discussion

Professor Didier Pittet, Director, Infection Control Programme and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine; Lead Advisor, WHO First Global Patient Safety Challenge: Clean Care is Safer Care

Professor Otto Cars, Executive Director, ReAct

Dr Ramanan Laxminarayan, Vice President for Research Policy, Public Health Foundation of India

Dr Bernard Vallat, Director General, World Organisation for Animal Health
Richard Bergström, Director General, European Federation of Pharmaceutical Industries and Associations

Dr Zafar Mirza, Coordinator, Public Health, Innovation and Intellectual Property, World Health Organization

Questions and discussion

13:30  End of conference and lunch

©The Royal Institute of International Affairs 2013